Skip to main content

Table 4 Clinical outcomes in the subsequent period by FVC% change group

From: Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis

  By lung-function change category (based on relative change in FVC%)a
  Stable [A] Marginal [B] Significant [C] Relative effect measure (95 % CI)
  (N = 250) (N = 98) (N = 142) [C] vs. [A] [C] vs. [B] [B] vs. [A]
  12-Month IR per Patient IRR
Rate of suspected AEx 0.26 0.47 0.74 2.87 (1.71–4.82) 1.58 (0.95–2.64) 1.82 (1.02–3.23)
  12-Month Risk OR
Risk of suspected AEx 19.2 % 37.1 % 50.9 % 4.37 (2.09–9.16) 1.76 (0.81–3.80) 2.49 (1.28–4.82)
Risk of progression 62.6 % 76.2 % 85.6 % 3.56 (1.66–7.64) 1.86 (0.81–4.26) 1.92 (0.91–4.04)
Mortalityb Risk by 12 Months HR
 Death due to any cause 6.4 % 13.1 % 28.0 % 5.05 (2.75–9.27) 1.85 (1.05–3.26) 2.73 (1.51–4.94)
 Death due to IPF 5.5 % 10.3 % 24.3 % 6.23 (2.96–13.14) 1.94 (1.01–3.70) 3.22 (1.59–6.53)
 Death due to AEx 5.0 % 9.3 % 13.1 % 3.91 (1.56–9.84) 1.22 (0.54–2.77) 3.21 (1.41–7.30)
  1. AEx acute exacerbation, IR incidence rate, IRR incidence rate ratio, OR odds ratio, HR hazard ratio
  2. aLung-function change categories were defined as the relative change in FVC% from index to approximately 6 months following IPF diagnosis. "Stable" was defined as decline <5 %. "Marginal" was defined as decline ≥5 % and <10 %, while "Significant" was defined as decline ≥10 %
  3. bKaplan-Meier survival analysis was used to estimate the risk of death by 12 months